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Abstract
Prostate cancer is a malignant disease of the urogenital system, which is the second most common cancer in 
men and one of the leading causes of death in male population. In Bandung City, Indonesia, no data are available 
regarding the profile of prostate cancer patients. This study aimed to determine the profile of prostate cancer 
patients treated at Dr. Hasan Sadikin General Hospital Bandung, Indonesia, which is the tertiary hospital in the 
most populated province in Indonesia, during the period of 2015–2019. This was a a retrospective descriptive 
study on secondary data from medical records. Results showed that most prostate carcinoma patients were was 
67.95 ± 8.946 years old with most of them (n=92, 81.4%) had a history of hypertension and 62 patients (54.9%) 
did not have any history of smoking. Most patients had 20–40 cc prostate volume with hard consistency and 
without nodules; a PSA level of >20 ng/mL; and a gleason score of 8-10 or poorly differentitated. Age affected 
increased incidence of prostate carcinoma with the highes prostate volume (20–40 cc). The  average PSA was 
504.66 ± 10.26 and the median gleason score was 8 (6-10). The highest prostate volume is 20–40 cc with hard 
consistency without nodule and the highest PSA value is >20 ng/mL with a Gleason score of 8–10, showing a 
poorly differentiated condition. 
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Profil Lima Tahun Pasien Penderita Kanker Prostat di Rumah Sakit Pusat 
di Indonesia
Abstrak
Kanker prostat adalah keganasan pada sistem urogenital yang merupakan kanker paling umum kedua pada pria 
dan salah satu penyebab utama kematian pada populasi pria. Belum ada data mengenai profil kanker prostat 
di Bandung. Penelitian ini bertujuan mengetahui profil pasien kanker prostat yang dirawat di Rumah Sakit Dr. 
Hasan Sadikin Bandung, Indonesia yang merupakan rumah sakit tersier di provinsi terpadat di Indonesia, selama 
periode 2015–2019. Jenis penelitian yang digunakan adalah penelitian deskriptif retrospektif. Sampel diambil 
berdasarkan data sekunder dari rekam medis. Hasil penelitian menunjukkan bahwa penderita karsinoma prostat 
terbanyak adalah 67,95 ± 8,946. Sebanyak 92 pasien (81,4%) pasien karsinoma memiliki riwayat hipertensi dan 
62 pasien (54,9%) tidak memiliki riwayat merokok. Sebagian besar pasien memiliki volume prostat 20–40 cc 
dengan konsistensi keras dan tanpa nodul, kadar PSA >20 ng/mL dan skor gleason 8–10 (berdiferensiasi buruk). 
Faktor usia memengaruhi peningkatan kejadian karsinoma prostat dengan volume prostat terbanyak pada 
kelompok 20–40 cc, rata-rata PSA 504.66 ± 1026.47 dan median skor gleason 8 (6-10).Pasien kanker prostat 
terbanyak berada pada kelompok usia 60–69 tahun dan 62 pasien tidak memiliki riwayat merokok. Pasien 
karsinoma prostat ditemukan volume terbesar, yaitu 20–40 cc dengan konsistensi keras tanpa nodul dengan nilai 
PSA tertinggi >20 ng/mL dan skor Gleason 8–10 yang menunjukkan berdiferensiasi buruk.
Kata kunci: Gleason, karsinoma prostate, PSA
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Introduction
Prostate carcinoma is cancer that originate 
from prostate epithelial cell.1  Prostate cancer 
is the second most commonly occurring cancer 
in adult males, approximately contributing to 
23% of malignancy cases.2,3,4 Prostate cancer is 
also the third leading causes of death associated 
with malignancies in men which increased 
significantly since 1990.3,5 The prevalence of 
prostate cancer in Indonesia in 2013 was 0.2% 
or an estimated 25,012 patients. Provinces with 
the highest prostate cancer prevalence were 
Yogyakarta, Bali, North Sulawesi, and South 
Sulawesi, namely 0.5%. The estimated absolute 
number of prostate cancer sufferers in North 
Sulawesi is 601 cases.6 So far, the known risk 
factors associated with prostate cancer are 
age, race and family history of prostate cancer. 
Generally prostate cancer affects older adult 
men with a peak at the age of 65–75 years.
Data on the number of cases of prostate 
carcinoma are still incomplete in Indonesia. 
Three Urology education centers (Jakarta, 
Bandung and Yogyakarta) recorded 761 cases in 
the last 8 years between 2004–2011. The number 
of prostate carcinoma patients at the National 
General Hospital Dr. Cipto Mangunkusumo 
and Dharmais Cancer Hospital in 2001–2006 
increased two times compared to 1995–2000, 
with an average number of cases per year was 
70–80 new cases.7 
Data in the USA shows more than 90% of 
prostate cancers are diagnosed at an earlier 
stage, whereas in Indonesia many are diagnosed 
at an advanced stage due to the delayed diagnosis. 
Neither national guidelines nor incidence data 
for prostate carcinoma in Indonesia at the 
time of this study are available. The unequal 
distribution of facilities and urologists in various 
parts of Indonesia has resulted in differences in 
diagnosing and managing prostate carcinoma 
patients. Therefore, this study aims to determine 
the profile of prostate carcinoma at Dr. Hasan 
Sadikin Hospital in Bandung for the period 2015 
to 2019.
Methods
This study used a prospective descriptive 
research design. This study aims to determine 
the profile of prostate carcinoma at Dr. Hasan 
Sadikin Hospital in Bandung from 2015 to 2019. 
Histologically confirmed prostate carcinoma 
patients that were registered in outpatient clinic 
Dr. Hasan Sadikin General Hospital Bandung who 
were willing to be included in this study from 
January 2015 to December 2019 were recruited. 
Patients with incomplete data were excluded 
from this study. All data were collected with total 
sampling. Variables collected in the study were 
Age, Blood Pressure, Smoking History, Body Mass 
Index, Prostat morphology, ISUP and Gleason 
Scores, Staging cancer, Cancer Stadium, Cancer 
metastasis, and Treatment Received. Statistical 
analysis was performed using IBM SPSS Statistics 
ver. 23.0 (IBM Co., Armonk, NY, USA).
Results
One hundred and five prostate carcinoma 
patients came to the urology clinic and met the 
inclusion and exclusion criteria during the 2015-
2019 period. There were 22 cases (19.5%), 19 
cases (16.8%), 35 cases (31.0%), and 12 cases 
(10.6%), and 5 cases (13.2%) respectively 
between 2015–2020 as shown in Table 1. The 
largest age group was 60-69 years, 52 (46.0%), 
as many as 92 (81.4%) prostate carcinoma 
sufferers also had hypertension, 62 (54.9%) 
patients smoked, and as many as 8 (70.8%) 
patients had normal body mass index, as shown 
in Table 2.
Most patients patients had 20–40 cc prostate 
volume range 47 (41.6%), hard consistency 
prostate 70 (61.9%), and without nodules in 65 
(57.5%) as shown in Table 3.
Most patients had PSA >20 ng/mL (83 
patients, 73.5%) as shown in Table 4.  Table 5 
shown Gleason score of 38 prostate carcinoma 
patients in this study with most of the have 8 
(4+4),(3+5),(5+3) and in stadium 4 in ISUP score.
Based on table 6, as many as 59 (52.2%) 
patients suffered from stage IV prostate 
carcinoma, as many as 96 (85.0%) patients did 
not experience metastases.
Table 1 Incidence of Prostate Carcinoma in   
 2015–2019
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Table 2 Characteristics of Prostate Carcinoma Patients













































Table 3  Distribution of Prostate Carcinoma 
  Patients Based on Prostate    
  Morphology






























Table 4 Distribution of Prostate Cancer 
  Patients Based on PSA levels
PSA levels Total (n) Percentage 
(%)
≤ 10 15 13.3
11-20 15 13.3
>20 83 73.5
Mean PSA 504.66 ± 10.26
The most commonly performed procedures 
for prostate carcinoma patients were radical 
prostatectomy which was performed in 40 
(35,3%) patients, followed by active surveilance 
29 (25.6%) patients, watchful waiting in 21 
(18.5%) patients, TRUP in 13 (11.5%) and 
radiotherapy 10 (8.8%) patients were shown in 
Table 7.
Discussion
In this study, one hundred and five prostate 
carcinoma patients recruited. Largest age group 
was within 60 - 69 years (46.0%) with average 
67.95±8.946. This similar with the research of 
Solang et al. who found that the most age group 
found in prostate carcinoma was in 61-70 years 
with 20 cases (37.0%).8  This is also in accordance 
with Siregar’s research which showed that 
the most age group in prostate cancer was 61-
70 years (25.3% of 194 total samples) and 
Zendrato’s study which also showed that the 
largest age group in prostate cancer was 61-70 
years (48.9% of 45 total samples).9,10 Various 
literature references state that prostate cancer 
is rare at <50 years of age.11 The risk of being 
diagnosed with prostate carcinoma is closely 
related to the age factor, where in men aged over 
50 years, the risk is almost 7 times higher than 
that of men aged 50–59 years and the risk of 
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death also increases to 21 times higher. However, 
sudden death caused by prostate carcinoma 
is more likely to occur in men diagnosed with 
prostate carcinoma in their 50s.12
Many studies have investigated and 
looked for factors such as age, physical status, 
psychiatric factors, lifestyle, socio-economic 
status and metabolic factors associated with 
prostate carcinoma. In a study conducted by 
Hwang et al, where in this study the categories 
of hypertension, diabetes and dyslipidemia 
were divided as risk factors.13,14 In this study, as 
many as 92 (81.4%) prostate carcinoma patients 
also had hypertension, as many as 62 (54.9%) 
Table 5 Distribution of Prostate Cancer Patient Based on Gleason Score
ISUP Score Total (n) Percentage (%)
1 2-6 11 9.7
2 7 (3+4) 10 8.8
3 7 (4+3) 17 15.0
4 8(4+4). (3+5). (5+3) 40 35.3
5 9-10 35 31.0
Table 6 Distribution of Prostate Cancer Patients Based on Staging and Metastasis
Staging Stadium Total (n) Percentage (%)
T1aN0M0G1 I 2 1.8
T1aN0M0G2,G3-4
T1b,cN0M0

























Tabel 7 Distribution of Prostate Cancer 
  Patients Based on Treatment
Treatment Total (n) Percentage (%)
Radioterapi 10 8.8
Radikal Prostatektomi 40 35.3
ADT 63 55.9
patients didn’t smoked, and 80 (70.8%) patients 
had a normal body mass index.
In this study, it was found that the highest 
distribution of prostate carcinoma based on 
PSA was at PSA levels> 20 ng/mL by 83 patients 
(73.5%) and the lowest was <10 ng/mL by 14 
patients (12.4%). This is consistent with research 
conducted by Erlangga which found that the 
highest frequency of prostate cancer had a PSA 
value> 10 ng/mL (65.9%).15 Lubis and Danarto 
also found that the highest frequency of prostate 
cancer had a PSA value> 10 ng/mL (87.9%).16 
Based on the research, PSA with a threshold 
value of 4 ng/mL has a sensitivity> 90% and 
a specificity <25%, whereas if the threshold 
value is 10 ng/mL the specificity increases up 
to 2 times. This is in accordance with the theory 
which says that the increased production of PSA 
indicates an increase in excess metabolism in 
the prostate which leads to malignancy so that 
PSA examination is an early detection of prostate 
cancer.15 An increase in PSA> 100 ng/mL before 
therapy is an important indicator of metastasis 
with positive predictive value is 100% so it is 
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necessary to carry out further examinations in 
the form of plain bone radiographs, CT or MRI.16 
In one study, it was found that the mean PSA 
levels in developed countries were lower, such 
as Japan and South Korea, namely between 15-
51 ng/mL, in developing countries varies from 
75-373 ng/mL. 17
Most pastient in study have  Gleason score of 
8-10 (poorly differentiated) as many as 75 cases 
(66.3%). The Gleason score is currently the most 
widely used method in the world to determine the 
histopathological degree of prostate carcinoma, 
however, until now, there are still many 
differences in studies regarding the relationship 
between the Gleason score and the patient’s age 
at the time of prostate carcinoma diagnosis. Zhou 
et al’s study found that among African Americans 
there was a tendency to increase Gleason scores 
in older men but not Caucasians, interestingly 
they found that those under 50 years of age were 
equally likely to have high Gleason scores in both 
races.18 in the anatomical pathology laboratory 
in West Sumatra found that the distribution of 
all Gleason scores was the same at <50 years of 
age, the 51–60 year age group was the most well 
differentiated (42.86%), while the 61–70 years, 
71–80 age group years and 81–90 years are 
mostly poorly differentiated, which are 46.03%, 
50%, and 62.50%, respectively.19
Based on table 4.6, as many as 59 (52.2%) 
patients had stage IV prostate carcinoma, as 
many as 54 (47.8%) patients did not experience 
metastases. The pathogenesis of prostate cancer 
metastases to bone is due to the presence of a 
venous plexus called the Batson plexus. Venous 
blood flow from the prostate will flow to the 
vertebral column and pelvis through the Batson 
plexus so that the spread of prostate cancer is 
found in the vertebrae, especially the lumbar 
and pelvic bones. Staging is one of the bases in 
considering the type of treatment and prognosis 
of the patient along with the Gleason score and 
PSA score.12,20
The most commonly performed procedures 
for prostate carcinoma patients were radical 
prostatectomy which was performed in 40 
(35,3%) patients, followed by active surveilance 
29 (25.6%) patients, watchful waiting in 21 
(18.5%) patients, TRUP in 13 (11.5%) and 
radiotherapy 10 (8.8%) patients. Radical 
prostatectomy is the main curative therapy in 
localized prostate carcinoma. Umbas et al said 
that hormonal therapy and TURP are still the 
therapeutic modalities most often chosen by 
urologists in Indonesia because the condition 
of patients who come is already at an advanced 
stage.17
In conclusion, that the most prostate cancer 
patients are in the 60–69 year age group for the 
period 2015–2019 in Dr. Hasan Sadikin General 
Hospital in Bandung. There were 62 patients 
with prostate carcinoma who did not had a 
smoking history. Prostate carcinoma patients 
found the largest volume range of 20–40cc 
with hard consistency without nodule with 
the highest PSA value >20 ng/mL. The highest 
Gleason score in this study was a score of 8–10 
(poorly differentiated). The most commonly 
performed procedures for prostate carcinoma 
patients were radical prostatectomy which was 
performed in 40 (35.3%) patients
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